Detalles de la búsqueda
1.
Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study.
Ann Hematol
; 101(9): 1905-1914, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35869984
2.
Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria.
Ann Hematol
; 101(9): 1971-1986, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35869170
3.
Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan.
Drugs R D
; 2024 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38727860
4.
Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and postmarketing settings.
Res Pract Thromb Haemost
; 8(4): 102416, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38812989
5.
Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study.
Adv Ther
; 41(5): 2050-2069, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38573482
6.
Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.
Adv Ther
; 40(4): 1571-1589, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36750531
7.
Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
Blood Adv
; 7(11): 2468-2478, 2023 06 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-36848639
8.
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial.
Lancet Haematol
; 9(9): e648-e659, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-36055332
9.
Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.
JAMA Oncol
; 6(2): 217-225, 2020 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31830211
10.
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus.
Hepatology
; 46(5): 1341-9, 2007 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-17929306
11.
Correction to: Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.
Adv Ther
; 40(12): 5591-5595, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37789229
12.
Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist.
Antivir Ther
; 12(5): 741-51, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-17713157
13.
Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.
Hum Pathol
; 43(9): 1363-75, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22204715
14.
Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer.
J Clin Oncol
; 26(24): 3979-86, 2008 Aug 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-18711188
15.
Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist.
J Immunother
; 27(6): 460-71, 2004.
Artículo
en Inglés
| MEDLINE | ID: mdl-15534490
Resultados
1 -
15
de 15
1
Próxima >
>>